Melophit 5 Tablet contains Melphalan 5mg, a potent alkylating agent widely used in oncology for the treatment of multiple myeloma and selected solid tumors such as ovarian cancer. The higher strength supports flexible dosing strategies in chemotherapy regimens aimed at disease control and remission maintenance.
Melphalan works by cross-linking DNA strands in rapidly dividing malignant cells, inhibiting DNA replication and triggering cell death. This cytotoxic action helps reduce tumor burden and slow disease progression when administered under specialist supervision.
For distributors and healthcare suppliers, Melophit 5 Tablet is a critical oncology therapy product, primarily supplied to cancer hospitals, oncology clinics, and tertiary care institutions. Ongoing requirements for oral chemotherapy agents in long-term cancer management ensure steady and specialized demand.
Adding Melophit 5 Tablet to your oncology and anticancer therapy segment strengthens portfolios across hospital supply chains, specialty pharmacies, export markets, and third-party manufacturing. Its established clinical role, dose flexibility, and importance in cancer treatment protocols make it a valuable product within pharmaceutical oncology distribution.